RxDoctor Payments Data

Karen Winterburn

Women's Health · Jamestown, NYNPI 1801857552

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $557 and has fallen 56.6% since, to $242 in 2025. Among women's health clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,756in general payments, 2019–2025

Across 87 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$317
  • Novo Nordisk$271
  • Therapeuticsmd, Inc.$155
  • Amgen$143
  • AbbVie$122
  • Lilly USA, LLC$121
  • plus $627 from 13 others

What the payments were for

  • Food & beverage$1,67195%
  • Education$855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,756 in reported general payments places this provider in the 90th percentile of 376 women's health providers in New York.

See all women's health providers in New York

Medicare billing

Part B allowed, 2024
$16,941
Medicare patients
121
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$12,111
Estradiol124$8,997
SlyndDrospirenone13$2,230
Clobetasol Propionate45$1,345
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$986
Norethindron-Ethinyl EstradiolNorethindrone Ac/Eth Estradiol17$940
ValacyclovirValacyclovir Hcl21$867
ProgesteroneProgesterone, Micronized34$672
Betamethasone Dipropionate12$637
Alendronate Sodium77$383
Fluoxetine Hcl19$307
Metronidazole15$293
Terconazole12$244
Venlafaxine Hcl ErVenlafaxine Hcl17$215
Norethindrone-E.Estradiol-Iron12$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$121$12,11112 claims
Exeltis, USA Inc.Slynd$80$2,23013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 376 women's health providers in New York.

Other women's health in Jamestown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →